# A Study of RBD1016 in CHB Participants

> **NCT05961098** · PHASE2 · COMPLETED · sponsor: **Suzhou Ribo Life Science Co. Ltd.** · enrollment: 48 (actual)

## Conditions studied

- Chronic Hepatitis b

## Interventions

- **DRUG:** RBD1016

## Key facts

- **NCT ID:** NCT05961098
- **Lead sponsor:** Suzhou Ribo Life Science Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-11
- **Primary completion:** 2025-04-29
- **Final completion:** 2025-10-15
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05961098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05961098, "A Study of RBD1016 in CHB Participants". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT05961098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*